Claims for Patent: 8,007,796

Summary for Patent: 8,007,796

Title:	Means and methods for the treatment of tumorous diseases
Abstract:	The invention relates to pharmaceutical means and methods for the prevention, treatment or amelioration of indolent or aggressive B cell non-Hodgkin lymphoma (B NHL) and B cell leukemia comprising the administration of a bispecific single chain antibody construct to a subject and the use of the bispecific single chain antibody construct for the preparation of a pharmaceutical composition for the prevention, treatment or amelioration of indolent or aggressive B cell non-Hodgkin lymphoma (B NHL) and B cell leukemia. The construct is to be administered for at least 1 week in specified daily doses. Moreover, the invention relates to kits comprising a bispecific single chain antibody construct to be used in accordance with this invention.
Inventor(s):	Baeuerle; Patrick (Gauting, DE), Kufer; Peter (Moosburg, DE), Klinger; Matthias (Gilching, DE), Leo; Eugen (Koln, DE)
Assignee:	Micromet AG (Munich, DE)
Application Number:	12/095,951
Patent Claims:	1. A method for the treatment or amelioration of indolent or aggressive B cell non-Hodgkin lymphoma (B NHL) or B cell leukemia, the method comprising the administration of a pharmaceutical composition comprising a bispecific single chain antibody construct to a subject in the need thereof, said bispecific single chain antibody construct comprising binding domains specific for human CD3 and human CD19, wherein the corresponding variable heavy chain regions (V.sub.H) and the corresponding variable light chain regions (V.sub.L) regions are arranged, from N-terminus to C-terminus, in the order, V.sub.L(CD19)-V.sub.H(CD19)-V.sub.H(CD3)-V.sub.L(CD3), V.sub.H(CD19)-V.sub.L(CD19)-V.sub.H(CD3)-V.sub.L(CD3), V.sub.H(CD3)-V.sub.L(CD3)-V.sub.H(CD19)-V.sub.L(CD19) or V.sub.H(CD3)-V.sub.L(CD3)-V.sub.L(CD19)-V.sub.H(CD19), wherein the bispecific single chain antibody construct is administered for at least 1 week in a daily dose of 10 .mu.g to 80 .mu.g per square meter patient body surface area and wherein the daily dose is administered over at least 6 h, and wherein each VL and VH region comprises a CDR1, CDR2, and CDR3 region. 2. The method according to claim 1, wherein the daily dose is administered over at least 10 h. 3. The method according to claim 1, wherein the daily dose is administered over at least 12 h. 4. The method according to claim 1, wherein the daily doses is administered over 24 h. 5. The method according to claim 1, wherein said V.sub.H and V.sub.L regions of said CD3 specific domain are from a CD3 specific antibody selected from the group consisting of: OKT-3, X35-3, VIT3, BMA030 (BW264/56), CLB-T3/3, CRIS7, YTH12.5, F111-409, TR-66, WT31, WT32, SPv-T3b, 11D8, XIII-141, XIII-46, XIII-87, 12F6, T3/RW2-8C8, T3/RW2-4B6, OKT3D, M-T301, SMC2 and F101.01. 6. The method according to claim 1, wherein said V.sub.H region of said CD3 specific domain comprises at least one CDR3 region comprising the amino acid sequence: SEQ ID NO. 11. 7. The method according to claim 1, wherein said V.sub.H region of said CD3 specific domain comprises at least one CDR2 region comprising the amino acid sequence: SEQ ID NO. 10. 8. The method according to claim 1, wherein said V.sub.H region of said CD3 specific domain comprises at least one CDR1 region comprising the amino acid sequence: SEQ ID NO. 9. 9. The method according to claim 1, wherein said V.sub.L region of said CD3 specific domain comprises at least one CDR3 region comprising the amino acid sequence: SEQ ID NO. 14. 10. The method according to claim 1, wherein said V.sub.L region of said CD3 specific domain comprises at least one CDR2 region comprising the amino acid sequence: SEQ ID NO. 13. 11. The method according to claim 1, wherein said V.sub.L region of said CD3 specific domain comprises at least one CDR1 region comprising the amino acid sequence: SEQ ID NO. 12. 12. The method according to claim 1, wherein said VH region of said CD3 specific domain comprises SEQ ID NO. 17, said VH region of said CD19 specific domain comprises SEQ ID NO. 15, said VL region of said CD3 specific domain comprises SEQ ID NO. 18 and/or said VL region of said CD19 specific domain comprises SEQ ID NO. 16. 13. The method according to claim 1, wherein said bispecific single chain antibody construct comprises an amino acid sequence selected from the group consisting of (a) an amino acid sequence as depicted in SEQ ID NOs 2, 4, 6, or 8; (b) an amino acid sequence encoded by a nucleic acid sequence as shown in SEQ ID NOs 1, 3, 5, or 7; and (c) an amino acid sequence encoded by a nucleic acid sequence which is degenerate as a result of the genetic code to a nucleotide sequence of (b), wherein said amino acid sequence is capable of specifically binding to CD3 and CD19. 14. The method according to claim 1, wherein said variable domains are connected by additional linker sequences. 15. The method according to claim 1, wherein the daily administration is continued for at least 2 weeks, at least 3 weeks or at least 4 weeks. 16. The method according to claim 1, wherein the pharmaceutical composition is administered in combination with one or more further pharmaceutical agents. 17. The method according to claim 1, wherein the pharmaceutical composition is administered to a human patient. 18. The method according to claim 1, wherein the bispecific single chain antibody construct is administered in a daily dose of less than 10 .mu.g to 80 .mu.g per square meter patient body surface area on the first day.

Details for Patent 8,007,796

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Amgen Inc.	BLINCYTO	blinatumomab	For Injection	125557	December 03, 2014		2025-12-16

International Patent Family for US Patent 8,007,796

Country	Patent Number	Estimated Expiration
South Africa	200806095
World Intellectual Property Organization (WIPO)	2007068354
United States of America	2022088196